研究者総覧

川島 秀俊 (カワシマ ヒデトシ)

  • 眼科学講座 教授
Last Updated :2021/11/23

研究者情報

ホームページURL

J-Global ID

研究キーワード

  • アポトーシス   免疫制御   免疫学的特異性   Fas   TUNEL染色   実験的ぶどう膜炎   角膜内皮   前房内免疫偏位   IRBP   Fasリガンド   B6gld   B6lpr   リンパ球   好中球   角膜移植   Th1細胞   ケモカイン   ヘルペス網膜炎   網膜炎   MIP-2   IP-10   単純ヘルペスウイルス   

経歴

  • 1999年 - 2000年  東京大学医学部・附属病院・分院助教授

研究活動情報

論文

  • Takahiko Hayashi, Hidenori Takahashi, Satoru Inoda, Toshiki Shimizu, Akira Kobayashi, Hidetoshi Kawashima, Takefumi Yamaguchi, Satoru Yamagami
    Scientific reports 11 1 17064 - 17064 2021年08月 
    The aim of this study was to compare aqueous humour (AqH) cytokine profiles before and after Descemet's membrane endothelial keratoplasty (DMEK) in eyes with bullous keratopathy (BK) and age-matched normal eyes. A total of 49 participants (mean age 75.0 ± 13.5 years) were divided into three groups: (1) BK patients scheduled for DMEK (BK group); (2) patients after DMEK (DMEK group; average postoperative time 1,018 ± 460 days); and (3) control participants without corneal endothelial disease scheduled for cataract surgery (control group). AqH (0.2 mL) was collected from all participants, and the levels of various AqH cytokines were simultaneously measured using a multiplex bead immunoassay. The DMEK group exhibited significantly lower concentrations of several pro-inflammatory cytokines, such as IL-1β, IL-5, IL-6, IL-10, and IL-8, and granulocyte colony stimulating factor than the BK group. In addition, the levels of IL-1β and IL-5 were significantly lower in the DMEK group than in the control group. The AqH levels of several pro-inflammatory cytokines were significantly reduced after DMEK, indicating that regeneration of the endothelial pump owing to the transplantation of a healthy endothelium might have a positive effect on anterior chamber inflammation.
  • Yusuke Arai, Hidenori Takahashi, Satoru Inoda, Shinichi Sakamoto, Xue Tan, Yuji Inoue, Satoko Tominaga, Hidetoshi Kawashima, Yasuo Yanagi
    Journal of clinical medicine 10 14 2021年07月 
    This study aimed to evaluate the long-term (24-month) efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This was a prospective multicenter intervention study. We evaluated 50 eyes in 50 patients with ME due to BRVO enrolled between October 2016 and September 2017. The patients received intravitreal aflibercept (IVA) injections according to a mTAE regimen for 24 months. This study reports the secondary endpoints of best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 24 months and compares them with previously reported primary endpoints. Compared with baseline BCVA and CST of 0.33 (0.27) and 488 (165) µm (mean (standard deviation)), respectively, BCVA and CST were significantly improved at 12 and 24 months (12 months: 0.059 (0.19) LogMAR and 299 (112) µm; 24 months: 0.034 (0.18) LogMAR and 272 (81) µm, respectively; both p < 0.0001). Over the 24-month period, the mean number of IVA injections and clinic visits was 7.4 (3.3) and 11.1 (2.0), respectively. The mTAE regimen of IVA injections for ME due to BRVO was effective for improving BCVA and reducing CST over 24 months. This regimen shows promise for reducing the number of injections and clinic visits.
  • Jo Moriya, Shinichi Sakamoto, Satoru Inoda, Hidenori Takahashi, Hidetoshi Kawashima
    Case Reports in Ophthalmology 12 1 283 - 287 2021年04月 
    Accidental intraocular lens (IOL) implantation into the corneal stroma is a rare clinical entity that can occur during the wound-assisted technique. In this report, we describe a case of an 81-year-old man who underwent cataract surgery in which the IOL was implanted into the corneal stroma with the wound-assisted technique, and we present changes in anterior segment optical coherence tomography. The IOL was removed and reinserted after widening the incision. Air tamponade was created by intracameral injection. An anterior chamber tap was performed 10 h later to reduce increased intraocular pressure. Interlayer separation of the corneal stroma was confirmed 30 min postoperatively but was corrected 4 days later. The patient’s best-corrected visual acuity (BCVA) was logMAR 0.30, and he had been diagnosed with age-related macular degeneration before surgery. Although the opacity of the corneal stroma persisted, BCVA improved to logMAR 0. When using the wound-assisted technique for IOL insertion, surgeons should take care not to implant the IOL into the corneal stroma.
  • ブロルシズマブ切替後内眼炎の投与前前房水中タンパク質濃度プロファイル
    橋本 悠人, 伊野田 悟, 高橋 秀徳, 吉田 花, 高橋 良太, 坂本 晋一, 新井 悠介, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 125 臨増 233 - 233 (公財)日本眼科学会 2021年03月
  • ブロルシズマブ投与後内眼炎を来した滲出型加齢黄斑変性6例の背景検討
    吉田 花, 新井 悠介, 高橋 秀徳, 橋本 悠人, 譚 雪, 伊野田 悟, 高橋 良太, 藤野 雄次郎, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 125 臨増 264 - 264 (公財)日本眼科学会 2021年03月
  • コーツ病に伴った黄斑円孔の1例
    橋本 悠人, 新井 悠介, 坂本 晋一, 高橋 秀徳, 井上 裕治, 牧野 伸二, 川島 秀俊
    眼科臨床紀要 13 10 697 - 698 眼科臨床紀要会 2020年10月
  • Yusuke Arai, Hidenori Takahashi, Satoru Inoda, Shinichi Sakamoto, Xue Tan, Yuji Inoue, Satoko Tominaga, Hidetoshi Kawashima, Yasuo Yanagi
    Journal of clinical medicine 9 8 2020年07月 
    PURPOSE: To assess the efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). METHODS: This prospective multicentre intervention study evaluated 50 eyes of 50 patients enrolled from October 2016 to September 2017. The patients received intravitreal aflibercept (IVA) injections on an mTAE regimen for a total of 12 months. The main outcome measures were best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 12 months. RESULTS: The baseline BCVA and CST were 0.33 (0.27) and 488 (171) µm (mean (standard deviation)), respectively. The BCVA and CST were significantly improved at month 12 (0.067 (0.19) LogMAR and 295 (110) µm; both p < 0.0001, paired t-test). The mean number of clinic visits and IVA injections was 6.71 (1.41) and 4.26 (0.71), respectively. The time to first recurrence from the first injection was most frequently 3 months. CONCLUSION: The mTAE regimen of IVA injections for ME due to BRVO effectively improved BCVA and reduced CST, and thus might be an effective therapy to reduce the number of injections and visits.
  • 高齢者の黄斑部新生血管の視力予後に関与する炎症性サイトカインの検討
    伊野田 悟, 高橋 秀徳, 譚 雪, 新井 悠介, 坂本 晋一, 井上 裕治, 藤野 雄次郎, 川島 秀俊, 柳 靖雄
    眼科臨床紀要 13 6 440 - 440 眼科臨床紀要会 2020年06月
  • 漿液性網膜剥離を伴う傾斜乳頭症候群における前房中炎症性サイトカイン濃度
    井上 裕治, 高橋 秀徳, 林 あゆみ, 長岡 広祐, 高橋 良太, 伊野田 悟, 坂本 晋一, 新井 悠介, 富永 聡子, 譚 雪, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 124 臨増 167 - 167 (公財)日本眼科学会 2020年03月
  • 粕谷 友香, 佐野 一矢, 牧野 伸二, 川島 秀俊
    臨床眼科 74 3 303 - 308 (株)医学書院 2020年03月 
    <文献概要>目的:妊娠高血圧腎症に伴う下垂体炎を報告する。症例:35歳,女性。妊娠高血圧腎症の管理目的に入院した。妊娠30週に緊急帝王切開術が施行された。妊娠25週頃より頭痛,左眼の霧視を自覚していたが分娩1週後,眼科的精査目的に紹介され受診した。視力は右0.05(1.2),左0.02(0.9),前眼部に異常はなかった。眼底は両眼とも高血圧に伴う軟性白斑,網膜出血がみられた。ゴールドマン視野検査では不規則な両耳側半盲がみられた。頭部MRIにて,トルコ鞍から鞍上部にかけてT2強調画像で軽度高信号を呈し,造影により均一に増強される腫瘤性病変が確認された。基礎値で下垂体機能低下症はなかったが,高張食塩水負荷試験+デスモプレシン負荷試験では部分型中枢性尿崩症の所見であった。下垂体後葉炎の疑いとして,ステロイド内服が開始された。内服1ヵ月後の左眼視力は(1.2)に改善し,下垂体病変は経時的に縮小した。発症から1年後,右眼の視野は不変であるが,左眼の視野はほぼ正常に改善した。結論:妊娠中の視力・視野障害の原因に下垂体炎があることを念頭に置く必要がある。
  • Yusuke Arai, Hidenori TakahashiI, Satoru Inoda, Xue Tan, Shinichi Sakamoto, Yuji Inoue, Yujiro Fujino, Hidetoshi Kawashima, Yasuo Yanagi
    PLoS One 15 3 2020年03月 [査読有り][通常論文]
  • Ichiya Sano, Hidenori Takahashi, Satoru Inoda, Shinichi Sakamoto, Yusuke Arai, Yuji Takahashi, Akira Ohkubo, Hidetoshi Kawashima, Chihiro Mayama
    AMERICAN JOURNAL OF OPHTHALMOLOGY 206 11 - 16 2019年10月 
    PURPOSE: To investigate changes in the interpupillary distance (IPD) after continual instillation of topical prostaglandin analogs (PGAs) in glaucoma patients as an objective indicator of prostaglandin-associated periorbitopathy (PAP).DESIGN: Retrospective, comparative case series.METHODS: A total of 152 institutional patients with glaucoma were enrolled in this study. Inclusion criteria were visual acuities exceeding 10/20 bilaterally and no intraocular surgery during observation. INTERVENTION/ OBSERVATION PROCEDURES: First-time bilateral instillation of bimatoprost, travoprost, latanoprost, or tafluprost and IPDs measured by automatic refractometry. IPDs, intraocular pressures (IOPs), and refractive errors were measured before and after continual drug administration (treatment, 2-24 months). MAIN OUTCOME MEASUREMENTS: Post-treatment changes in IPDs. A total of 61 untreated patients served as controls.RESULTS: The IPDs shortened significantly (P < 0.001) after treatment ( - 0.80 +/- 2.1 mm); the IPDs of control subjects remained unchanged (0.05 +/- 0.96 mm; P = 0.69). The IPD change after bimatoprost instillation (- 2.20 +/- 0.97 mm) was significantly (P < 0.001) greater than with other PGAs (- 0.65 +/- 2.09 mm). The IOPs decreased significantly (P < 0.001) (- 3.7 +/- 4.3 mm Hg); the refractive errors did not change significantly (P < 0.099) (- 0.07 +/- 0.69 diopter) posttreatment. The percentages of subjects with 2-mm or greater decreases in IPD after bimatoprost, travoprost, latanoprost, or tafluprost were 85.7%, 20.0%, 18.2%, and 17.2%, respectively, and with 3-mm or greater decreases in IPD 35.7%, 12.0%, 14.5%, and 12.1%, respectively. The specificities were 93.4% and 100% in the control group, respectively, with IPD threshold changes of 2 and 3 mm or more, respectively.CONCLUSIONS: The IPD decreased significantly after topical PGAs within 24 months. The effect was significantly greater with bimatoprost than with other PGAs. The noninvasive, immediate automatic refractometry measurement may be an objective numerical indicator of PAP. (C) 2019 Elsevier Inc. All rights reserved.
  • 網膜光凝固を施行した未熟児網膜症の視力に関する検討
    粕谷 友香, 渡辺 芽里, 新井 悠介, 牧野 伸二, 川島 秀俊
    眼科臨床紀要 12 9 721 - 721 眼科臨床紀要会 2019年09月
  • 近藤 由佳, 新井 悠介, 高橋 秀徳, 坂本 晋一, 伊野田 悟, 佐野 一矢, 井上 裕治, 川島 秀俊
    臨床眼科 73 8 1039 - 1044 (株)医学書院 2019年08月 
    <文献概要>目的:網膜静脈分枝閉塞症(BRVO)発症後の硝子体出血に対し硝子体手術を行った症例から,手術成績と網膜光凝固(PC)の必要性について検討した。対象と方法:対象は2013年4月〜2018年3月に自治医科大学眼科でBRVO発症後に硝子体出血を生じた眼に対し硝子体手術を施行した46例46眼。術前PCの有無,術前・術後視力,術後視力と術前PCの有無,無血管野の部位と術後視力,術中・術後合併症について後ろ向きに検討した。結果:硝子体手術前に31例(67%)でPCが施行されていた。術後視力1.0以上は29例(63%)で得られた。術前PCの有無と術後視力との間には関連はなく,網膜血管アーケード内に無血管野があるものでは術後視力が不良であった。術中・術後合併症は10例にみられた。結論:術前にPCが施行された症例が多かったが,術後視力は良好であった。術前PCの有無は術後視力に影響はなかった。PCの必要性についてはさらに検討が必要と考えられた。
  • 深層学習による光干渉断層計像からの最高矯正視力推測
    伊野田 悟, 高橋 秀徳, 新井 悠介, 反保 宏信, 坂本 晋一, 松井 良諭, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 123 臨増 291 - 291 (公財)日本眼科学会 2019年03月
  • 網膜光凝固を施行した未熟児網膜症の視力に関する検討
    粕谷 友香, 渡辺 芽里, 新井 悠介, 牧野 伸二, 川島 秀俊
    日本眼科学会雑誌 123 臨増 234 - 234 (公財)日本眼科学会 2019年03月
  • 視力良好な加齢黄斑変性に対するアフリベルセプトの視力維持の条件検討
    伊野田 悟, 高橋 秀徳, 新井 悠介, 坂本 晋一, 井上 裕治, 藤野 雄次郎, 川島 秀俊, 柳 靖雄
    眼科臨床紀要 11 9 708 - 708 眼科臨床紀要会 2018年09月
  • 滲出型加齢黄斑変性におけるpachyvessel所見の有無と炎症性サイトカインの関連
    恩田 昌紀, 高橋 秀徳, 井上 裕治, 譚 雪, 新井 悠介, 高橋 良太, 伊野田 悟, 坂本 晋一, 佐野 一矢, 藤野 雄次郎, 川島 秀俊, 柳 靖雄
    眼科臨床紀要 11 9 718 - 718 眼科臨床紀要会 2018年09月
  • Takayuki Fusumae, Koji Kamiya, Takeo Maekawa, Mayumi Komine, Satoru Murata, Satoru Inoda, Ryota Takahashi, Hidetoshi Kawashima, Mamitaro Ohtsuki
    The Journal of dermatology 45 6 e159-e160  2018年06月 [査読有り][通常論文]
  • 網脈絡膜萎縮発症時に脈絡膜肥厚と脈絡膜から色素上皮上への滲出が観察された1例
    粕谷 友香, 新井 悠介, 高橋 秀徳, 伊野田 悟, 坂本 晋一, 井上 裕治, 川島 秀俊, 柳 靖雄
    眼科臨床紀要 11 5 402 - 402 眼科臨床紀要会 2018年05月
  • 滲出型加齢黄斑変性におけるpachyvessel所見の有無と炎症性サイトカインの関連
    恩田 昌紀, 高橋 秀徳, 井上 裕治, 譚 雪, 新井 悠介, 高橋 良太, 伊野田 悟, 坂本 晋一, 佐野 一矢, 藤野 雄次郎, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 122 臨増 177 - 177 (公財)日本眼科学会 2018年03月
  • 深層学習によるカラー眼底写真からの脈絡膜厚推測 多施設での妥当性検討
    新井 悠介, 高橋 秀徳, 山下 高明, 長谷川 哲也, 大上 智弘, 園田 祥三, 田中 克明, 反保 宏信, 伊野田 悟, 坂本 晋一, 梯 彰弘, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 122 臨増 235 - 235 (公財)日本眼科学会 2018年03月
  • Shinichi Sakamoto, Hidenori Takahashi, Yuji Inoue, Yusuke Arai, Satoru Inoda, Natsuko Kakinuma, Yujiro Fujino, Tatsuro Tanabe, Hidetoshi Kawashima, Yasuo Yanagi
    Clinical ophthalmology (Auckland, N.Z.) 12 1137 - 1147 2018年 [査読有り][通常論文]
     
    Purpose: We report the 2-year outcomes of intravitreal aflibercept (IVA) for exudative age-related macular degeneration (AMD) with good visual acuity (VA) and examine the baseline factors associated with good visual outcome. Materials and methods: This multicenter, prospective study evaluated 39 eyes (39 AMD patients) enrolled from August 2013 to August 2014 at 12 and 24 months. Only patients with initial best-corrected VA (BCVA) >0.3 logarithm of the minimum angle of resolution (20/40 Snellen) were eligible. Three consecutive monthly IVA injections were followed by 2 monthly injections for 12 months. Thereafter, patients received injections on a treat- and-extend regimen for up to 24 months. Outcome measures included BCVA and central macular thickness (CMT) at 12 and 24 months. Post hoc analysis, BCVA, and CMT were evaluated by AMD types (typical AMD [tAMD], type 1, and type 2 polypoidal choroidal vasculopathy [PCV]). Baseline characteristics and BCVA associations were evaluated with linear regression analysis and Student's t-test. Results: Mean age was 69 years and 26 of 39 eyes were male. tAMD, type 1 and type 2 PCV occurred in 18, 12, and 9 eyes, respectively. Baseline mean BCVA was 0.097 logarithm of the minimum angle of resolution (20/25 Snellen) and showed significant improvement to 0.058 (20/22 Snellen, P=0.03) at 12 months and 0.066 (20/23) at 24 months. CMT improved significantly from 320 (99) µm (mean [SD]) to 250 (93) µm (P=0.002) at 12 months and 240 (93) µm (P=0.0005) at 24 months. BCVA and CMT were not significantly different among the three groups. Only subretinal hemorrhage (SRH) was significantly associated with improved BCVA. BCVA change from baseline was -0.12 with SRH and -0.011 without SRH (P=0.017) at 12 months. Conclusion: IVA showed good efficacy for exudative AMD with good VA at 24 months. tAMD and type 1 and 2 PCV showed similar prognosis. Baseline SRH predicted favorable long-term vision in AMD with good VA.
  • Shinichi Sakamoto, Hidenori Takahashi, Xue Tan, Yuji Inoue, Yoko Nomura, Yusuke Arai, Yujiro Fujino, Hidetoshi Kawashima, Yasuo Yanagi
    British Journal of Ophthalmology 102 4 448 - 454 2018年 [査読有り][通常論文]
     
    PURPOSE: To determine changes in multiple cytokine concentrations in the anterior chamber during the induction phase of ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD). METHODS: This prospective study included 48 treatment-naïve neovascular AMD eyes of 48 patients who received three consecutive monthly injections of ranibizumab at the Japan Community Health Care Organization Tokyo Shinjuku Medical Center between November 2010 and August 2012. We collected ~0.2 mL aqueous humour before the first and third (2 months later) injections. Controls were 80 eyes with cataracts without retinal disease. The cytokines C-X-C motif chemokine ligand 1 (CXCL1), interferon-γ-induced protein 10 (IP-10), C-X-C motif chemokine ligand 12 (CXCL12), C-X-C motif chemokine ligand 13 (CXCL13), monocyte chemoattractant protein 1 (MCP-1), CCL11, C-C motif chemokine ligand 11 (CCL11), interleukin-6 (IL-6), interleukin-10 (IL-10) and matrix metalloproteinase 9 (MMP-9) were analysed using multiplex cytokine assays. RESULTS: Mean ages of the patients with AMD and controls were 73 and 75 years, respectively, and 31 (65%) and 37 (46%) subjects were men, respectively. Polypoidal choroidal vasculopathy was found in 27 eyes (56%). Mean concentrations of cytokines in aqueous humour in patients with neovascular AMD before the first and third ranibizumab injections were as follows (in pg/mL): CXCL1, 8.4 and 3.3; IP-10, 110 and 55; CXCL12, 480 and 240; CXCL13, 9.2 and 2.6; MCP-1, 620 and 220; CCL11, 7.1 and 2.8; IL-6, 5.9 and 1.6; IL-10, 0.15 and 0.015 (all p<0.0001), and MMP-9, 0.92 and 1.5 (p=0.0216), respectively. Concentrations of all cytokines decreased significantly after two consecutive ranibizumab injections, except for MMP-9, which increased significantly. CONCLUSIONS: After two monthly consecutive antivascular endothelial growth factor injections, inflammatory cytokine levels in the aqueous humour of the eyes with AMD were strongly suppressed, while MMP-9 levels increased.
  • Shin-Ichi Sakamoto, Shinji Makino, Hidetoshi Kawashima
    Journal of general and family medicine 18 6 456 - 457 2017年12月
  • 深層学習によるカラー眼底写真からの脈絡膜厚推測
    反保 宏信, 高橋 秀徳, 添田 めぐみ, 高橋 良太, 伊野田 悟, 坂本 晋一, 新井 悠介, 井上 裕治, 川島 秀俊, 柳 靖雄
    眼科臨床紀要 10 10 873 - 873 眼科臨床紀要会 2017年10月
  • BRAF阻害薬ベムラフェニブ使用中にVogt-小柳-原田病を発症した1例
    伊野田 悟, 吉田 淳, 高橋 良太, 伏間江 貴之, 大槻 マミ太郎, 川島 秀俊
    眼科臨床紀要 10 10 873 - 873 眼科臨床紀要会 2017年10月 [査読有り][通常論文]
  • 高橋 良太, 伊野田 悟, 吉田 淳, 森本 哲, 川島 秀俊
    あたらしい眼科 34 5 718 - 721 (株)メディカル葵出版 2017年05月 [査読有り][通常論文]
     
    当初不全型Behcet病と診断された11歳の女児にコルヒチン治療を開始したが、有害事象によって治療継続が困難であったため、低用量副腎皮質ステロイド薬に切り替えた。その5ヵ月後、両眼にぶどう膜炎を発症し完全型Behcet病と診断した。コルヒチン治療に不耐、HLA-A26陽性などを総合的かつ慎重に検討し、インフリキシマブ治療を導入した。導入後、主症状4症状と副症状(股関節痛)は改善し、その後再燃を認めていない。小児Behcet病ぶどう膜炎に対するインフリキシマブ治療の報告は少ないが、非常に有効な治療と考えられ、さらなる臨床経験の蓄積が期待される。(著者抄録)
  • 深層学習によるカラー眼底写真からの脈絡膜厚推測
    反保 宏信, 高橋 秀徳, 添田 めぐみ, 高橋 良太, 伊野田 悟, 坂本 晋一, 新井 悠介, 井上 裕次, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 121 臨増 213 - 213 (公財)日本眼科学会 2017年03月
  • Hidenori Takahashi, Hironobu Tampo, Yusuke Arai, Yuji Inoue, Hidetoshi Kawashima
    PloS one 12 6 e0179790  2017年 
    PURPOSE: Disease staging involves the assessment of disease severity or progression and is used for treatment selection. In diabetic retinopathy, disease staging using a wide area is more desirable than that using a limited area. We investigated if deep learning artificial intelligence (AI) could be used to grade diabetic retinopathy and determine treatment and prognosis. METHODS: The retrospective study analyzed 9,939 posterior pole photographs of 2,740 patients with diabetes. Nonmydriatic 45° field color fundus photographs were taken of four fields in each eye annually at Jichi Medical University between May 2011 and June 2015. A modified fully randomly initialized GoogLeNet deep learning neural network was trained on 95% of the photographs using manual modified Davis grading of three additional adjacent photographs. We graded 4,709 of the 9,939 posterior pole fundus photographs using real prognoses. In addition, 95% of the photographs were learned by the modified GoogLeNet. Main outcome measures were prevalence and bias-adjusted Fleiss' kappa (PABAK) of AI staging of the remaining 5% of the photographs. RESULTS: The PABAK to modified Davis grading was 0.64 (accuracy, 81%; correct answer in 402 of 496 photographs). The PABAK to real prognosis grading was 0.37 (accuracy, 96%). CONCLUSIONS: We propose a novel AI disease-staging system for grading diabetic retinopathy that involves a retinal area not typically visualized on fundoscopy and another AI that directly suggests treatments and determines prognoses.
  • 加齢黄斑変性に対するラニビズマブとアフリベルセプト短期予後の差と中心網膜厚の関連
    坂本 晋一, 高橋 秀徳, 井上 裕治, 柳 靖雄, 佐藤 彩, 竹澤 美貴子, 田邊 樹郎, 藤野 雄次郎, 川島 秀俊
    日本眼科学会雑誌 120 臨増 276 - 276 (公財)日本眼科学会 2016年03月
  • Hidenori Takahashi, Yoko Nomura, Junko Nishida, Yujiro Fujino, Yasuo Yanagi, Hidetoshi Kawashima
    Investigative ophthalmology & visual science 57 2 462 - 6 2016年02月 
    PURPOSE: Commercially available enzyme-linked immunosorbent assay (ELISA) kits are often used to monitor vascular endothelial growth factor (VEGF) levels in exudative age-related macular degeneration. To test their accuracy, this study performed measurements using the ELISA kits in the presence of anti-VEGF drugs. METHODS: The concentrations of bevacizumab, pegaptanib, or ranibizumab at 28 days and aflibercept at 28 and 56 days after an injection were estimated based on previous pharmacokinetic studies. Vascular endothelial growth factor concentrations were measured with two widely used VEGF ELISA kits in the presence of anti-VEGF drugs or control mouse immunoglobulin G (IgG). The monocyte chemotactic protein-1 (MCP-1) ELISA kit was used as a non-VEGF ELISA control kit. RESULTS: The concentrations of aflibercept, bevacizumab, pegaptanib, and ranibizumab were estimated at 0.14 to 7.2, 4.9, 8.6, and 0.11 to 1.1 μg/mL, respectively. ELISA underestimated the VEGF concentration 2- to 100-fold lower in the presence of an anti-VEGF drug, except for pegaptanib, at all VEGF concentrations tested (7.8-1500 pg/mL). Vascular endothelial growth factor at 1000 pg/mL was measured as 92, 150, and 170 pg/mL in the presence of aflibercept (7.2 μg/mL), bevacizumab (4.9 μg/mL), and ranibizumab (1.1 μg/mL), respectively (all P < 0.0001), and the measured VEGF concentration decreased proportionately by 90% to 92% with aflibercept, 85% to 94% with bevacizumab, and 83% to 99% with ranibizumab. The control mouse IgG did not interfere with the measurement of VEGF. Ranibizumab did not affect the measurements with MCP-1 ELISA. CONCLUSIONS: Investigators should exercise caution when interpreting measurements of VEGF ELISA in patients being treated with an anti-VEGF drug.
  • 伊野田 悟, 吉田 淳, 川島 秀俊
    臨床眼科 69 6 869 - 873 (株)医学書院 2015年06月 [査読有り][通常論文]
     
    目的:抗好中球細胞質抗体(ANCA)関連血管炎に視神経障害が発症したと推定される1症例の報告。症例:74歳女性が右眼視力の低下で受診した。以前からぶどう膜炎が両眼にあり,プレドニゾロンを内服していた。右眼に白内障手術と難聴の既往があった。所見:矯正視力は右0.1,左1.2で,眼圧は右5mmHg,左16mmHgであった。右眼に前房の炎症所見と硝子体混濁があった。蛍光眼底造影で後部ぶどう膜炎の所見があった。左眼には病的所見はなかった。MPO-ANCAが高値で,難聴の既往と合わせ,内科でANCA関連血管炎と診断された。プレドニゾロン内服を継続した。5ヵ月後に左眼視力が低下し,その3週間後に受診した。矯正視力は右0.3,左0であり,蛍光眼底造影で左眼乳頭の低蛍光があった。ANCA関連血管炎に関連した後部虚血性視神経症が推定された。左眼視力は回復しなかった。結論:ANCA関連血管炎に関連した視神経症は,多彩で難治性であることを本症例は示している。(著者抄録)
  • 網膜静脈閉塞症慢性期における前房中炎症性サイトカイン濃度
    伊野田 悟, 高橋 秀徳, 譚 雪, 垣沼 奈津子, 野村 陽子, 坂本 晋一, 新井 悠介, 富永 聡子, 佐藤 彩, 藤野 雄次郎, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 119 臨増 164 - 164 (公財)日本眼科学会 2015年03月
  • 滲出型加齢黄斑変性に対する抗血管内皮増殖因子療法中の過度な網膜菲薄化と視力低下
    高橋 秀徳, 坂本 晋一, 垣沼 奈津子, 富永 聡子, 佐藤 彩, 竹澤 美貴子, 斎藤 由香, 斎藤 信一郎, 新井 悠介, 藤野 雄次郎, 川島 秀俊, 柳 靖雄
    日本眼科学会雑誌 119 臨増 241 - 241 (公財)日本眼科学会 2015年03月
  • 加齢黄斑変性に対するラニビズマブ投与推奨から実際の投与までの遅れと視力予後の関連
    高橋 秀徳, 佐藤 彩, 竹澤 美貴子, 藤野 雄次郎, 柳 靖雄, 川島 秀俊
    眼科臨床紀要 6 10 834 - 835 眼科臨床紀要会 2013年10月
  • 加齢黄斑変性および正常対象眼における後部硝子体剥離と各種サイトカイン濃度の関連
    高橋 秀徳, 譚 雪, 柳 靖雄, 野村 陽子, 藤野 雄次郎, 川島 秀俊
    日本眼科学会雑誌 117 臨増 330 - 330 (公財)日本眼科学会 2013年03月
  • Atsushi Yoshida, Toshikatsu Kaburaki, Kimiko Okinaga, Mitsuko Takamoto, Hidetoshi Kawashima, Yujiro Fujino
    Japanese journal of ophthalmology 56 6 536 - 43 2012年11月 
    PURPOSE: To examine the factors affecting the efficacy of infliximab (IFX) as a treatment for uveitis in Behçet's disease. METHODS: Clinical records of 29 patients with refractory uveoretinitis were examined retrospectively for the period between 6 months before the initiation of IFX therapy to 12 months thereafter. The patients were divided into two groups based on the absence (Group 1) or occurrence (Group 2) of ocular inflammatory attacks during the observation period after IFX therapy, and the clinical records of the groups were compared RESULTS: The mean age at onset of ocular inflammation in Group 1 patients (n = 17) was lower than that in Group 2 patients (n = 12) (p = 0.023). Compared to Group 2 patients, the period from onset to IFX therapy in Group 1 was longer (p = 0.037), and the frequency of ocular inflammatory attacks before IFX therapy was lower (p = 0.013). The rates of ocular fundus attacks before IFX therapy were 0.82 ± 0.28 in Group 1 and 0.96 ± 0.10 in Group 2 (p = 0.040). Three of 33 (9.1 %) eyes in Group 1 and nine of 24 eyes (37.5 %) in Group 2 had an improved best-corrected visual acuity of >0.2 logarithm of the minimal angle resolution (p < 0.01). CONCLUSIONS: Patients in Group 1 tended to have fewer intraocular attacks (fewer fundus attacks in particular) prior to IFX therapy and have a longer period from onset of intraocular inflammation to IFX therapy. The improvement of the BCVA in Group 2 tended to be better.
  • 伊藤 華江, 國松 志保, 保沢 こずえ, 近藤 玲子, 熊谷 知子, 平林 里恵, 金井 美佳, 牧野 伸二, 青木 由紀, 川島 秀俊, 小野 浩
    眼科臨床紀要 5 6 557 - 560 眼科臨床紀要会 2012年06月 
    目的:ロービジョン患者の運転実態調査を施行し、求心性視野狭窄患者に、運転の危険性を認知させる目的でドライビングシミュレータ(DS)を導入したので報告する。対象および方法:2007年10月〜2011年4月までに自治医科大学附属病院ロービジョン外来を受診した119例を対象に、運転歴、事故歴、運転時間、運転の目的について聴取した。DSが導入された2010年10月以降には、運転免許証をもつ視野狭窄患者6例に求心性視野狭窄患者用DSを施行した。結果:119例中54例に運転歴があり、12例(10.1%)は、ロービジョン外来受診時に運転を継続していた。12例中4例が過去5年間に事故を起こしていた。DSを施行した6例では、標識や信号は認識できるものの、側方からの車や子供の飛び出しに、全く気づかず衝突した場面が多かった。結論:DSは患者に自分の運転の危険性を自覚させるのに有用であった。(著者抄録)
  • Toshikatsu Kaburaki, Fumiyuki Araki, Mitsuko Takamoto, Kimiko Okinaga, Atsushi Yoshida, Jiro Numaga, Yujiro Fujino, Hidetoshi Kawashima
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 248 5 709 - 14 2010年05月 
    BACKGROUND: Recent publications have suggested considerable improvements in the clinical outcomes of ocular Behcet's disease (BD) patients. However, the long-term time course of clinical ocular features of BD in recent cases remains largely unknown. In this study, we investigated annual time-course changes of best-corrected visual acuity (BCVA) during ocular convalescent stages, as well as annual frequency of ocular attacks during the initial 10 years of follow-up in patients with BD. METHODS: We studied 75 eyes in 39 patients (31 men, eight women) with BD, who were referred to our hospital between 1980 and 1996 within 1 year after the initial ocular attack and followed them up continuously for more than 10 years. The clinical courses of BCVA at the ocular convalescent stage from the onset of ocular disease were retrospectively examined, and the numbers of ocular attacks per eye per year were determined. RESULTS: Mean BCVA was 0.59 at 1 year, 0.31 at 3 years, and 0.12 at 10 years from the onset of ocular disease, while the numbers of ocular attacks per eye were 4.1 +/- 3.1 at 1 year, 2.2 +/- 1.9 at 5 years, and 1.4 +/- 1.8 at 10 years. Ocular attacks were still observed in 33 eyes (45%) of 21 patients (54%) with BD even after 10 years. Final BCVA in 42 eyes (56%) became lower than 0.5. The major reasons for poor visual prognosis were macular atrophy (41%) and chorioretinal atrophy (26%). CONCLUSIONS: The decline of BVCA continued, and nearly half the patients still suffered from ocular attacks at 10 years after the onset of ocular BD.
  • Kyoko Ono, Shiho Kunimatsu, Jiro Numaga, Toshikatsu Kaburaki, Yujiro Fujino, Hidetoshi Kawashima
    Clinical & experimental ophthalmology 31 4 365 - 6 2003年08月
  • Toshikatsu Kaburaki, Yujiro Fujino, Hidetoshi Kawashima, Guillermo Merino, Jiro Numaga, Jun Chen, Kouji Matsushima
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 241 5 353 - 8 2003年05月 
    BACKGROUND: Chemokines are a family of chemoattractants of leukocytes that play a critical role for leukocyte recruitment in various inflammatory diseases. The purpose of this study is to investigate the involvement of chemokines, interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) in the peripheral blood, with a special reference to disease activities of the patients with Behçet's disease (BD). METHODS: The study population consisted of totally 55 patients with BD who had panuveitis (20 patients with active BD, 35 patients with inactive BD) as well as 19 healthy volunteers as control. Disease activity was defined according to the existence of ocular inflammation. IL-8 and MCP-1 concentration levels in the plasma and whole-blood samples were measured by enzyme-linked immunosorbent assay. Whole-blood samples were obtained by lysing cell membranes of peripheral blood cells. RESULTS: Most of the plasma IL-8 samples were below the detectable limit. Whole-blood IL-8 levels were readily measured. The levels in the patients with active BD were significantly higher than the other two groups. The patients with active and inactive BD showed higher plasma and whole-blood levels of MCP-1 than controls. The plasma and whole-blood MCP-1 levels of the samples collected at the same time showed a linear correlation. CONCLUSION: A close relationship was found to exist between the cell-associated IL-8 and the disease activity, while a persistent role of MCP-1 was observed in BD. Measuring the whole-blood levels of chemokines is useful for monitoring the disease activity.
  • 裂孔原性硝子体出血をきたした肉芽腫性ぶどう膜炎の1例
    堀 秀行, 釜田 恵子, 酒井 理恵子, 牧野 伸二, 川島 秀俊, 清水 昊幸, 大久保 彰
    眼科臨床医報 92 11 1642 - 1642 眼科臨床医報会 1998年11月
  • 牧野 伸二, 川島 秀俊, 橋本 尚子
    臨床眼科 51 3 317 - 320 (株)医学書院 1997年03月 
    47歳男の地図状脈絡膜炎例に,走査レーザー検眼鏡(SLO)の微小視野計測を行った.SLO微小視野計測は眼底をモニターしながら網膜感度の測定が可能であり,その結果をフルオレセイン蛍光造影(FA),及びインドシアニングリーン蛍光造影(IA)の写真上にプロットして検討した.網脈絡膜萎縮巣の中でも,絶対暗点を呈した部位はFA,IAで造影後期まで低蛍光が持続した部位であり,又,IAで造影後期になって過蛍光がみられた部位は相対暗点となっていた

MISC



Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.